Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus gemcitabine and cisplatin in recurrent or metastatic nasopharyngeal carcinoma
CTR20221176Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in nasopharyngeal carcinoma (NPC), sponsored by Qilu Pharmaceutical. Started Aug 2022; status: completed.
02
Drugs
QL1706
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20221176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221176.